Type 1 diabetes is caused by absolute lack of insulin, so the clinical treatment must be insulin supplementation, and insulin pro-secretory agents are not effective for type 1 diabetes. So what is the specific application scheme of type 1 diabetes in practice? There are two commonly used methods, one is multiple daily insulin injections (MDI); the other is continuous subcutaneous insulin infusion (CSSII). 1. MDI (multiple daily insulin injections) (1) Basal insulin can be given by intermediate-acting insulin, long-acting insulin or long-acting insulin analogues, and mealtime insulin can be given by short-acting insulin, or rapid-acting insulin analogues. (2) Compared with medium-acting insulin, long-acting insulin analogs have better fasting glucose control and lower risk of nocturnal hypoglycemia. 2. CSII (continuous subcutaneous insulin infusion) (1) Using an artificial intelligence-controlled insulin input device, CSII short-acting insulin or rapid-acting insulin analogues provide basal and mealtime insulin, which can mimic the physiological insulin secretion pattern. (2) Intermediate-acting insulin, long-acting insulin, long-acting insulin analogues and premixed insulin cannot be used in CSII. (3) Rapid-acting insulin analogues are more advantageous in CSII because of their fast absorption and rapid onset of action. The clinic can make a comprehensive assessment according to the patient’s condition and economic status, and flexibly choose a suitable treatment plan to achieve the goal of glycemic control and prevent the occurrence of complications.